QNCX ▲ +2.5% - Quince Therapeutics, Inc.
$QNCX - Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Quince Therapeutics rose 2.5% after announcing it will host a virtual key opinion leader event on September 28, 2026, to discuss its LAM-001 candidate as a potential treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). The event signals the company's continued clinical development of the program and its effort to build support among influential physicians in the space.
17-SEP-2026 08:00 AM ET
Share this post
More filings for $QNCX
QNCX - Quince Therapeutics, Inc. - SEC Filing Update (14-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 14, 2026QNCX - Quince Therapeutics, Inc. - SEC Filing Update (14-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 14, 2026QNCX ▲ +3.8% - Quince Therapeutics, Inc.Oct 9, 2026QNCX ▼ -1.4% - Quince Therapeutics, Inc.Sep 3, 2026QNCX - Quince Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026QNCX - Quince Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $QNCX filing history →💬 Comments
Loading comments…
Leave a comment
